Table 25Studies of persistence with ACEIs and ARBs

StudyDurationACEIsARBs
ContinuedSwitchedDiscontinuedContinuedSwitchedDiscontinued
Randomized trials
Saito et al., 2004716 mo71%28%2%89%9%2%
Koylan et al., 2005896 mo~ 82%--~ 89%--
Hosohata et al., 20075012 mo55%--88%--
Veronesi et al.,200710024 mo61.5%--68.5%--
Longitudinal cohort studies
Hasford et al., 2002491 yr42%--44.7 to 60.8%--
Mazzaglia et al., 20051141 yr~ 50%~ 8%~ 42%~ 50%~ 10%~ 40%
Bloom et al., 1998118/Conlin et al., 20011211 yr58%9%33%64%7%29%
4 yr46.5%18.9%34.6%50.8%16.5%32.7%
Erkens et al., 20051241 yr59.7%--62.0%--
Marentette et al., 20021251 yr--~ 35%--~ 15%
Bourgault et al., 20051191 yr--41%--34%
2 yr--53%--44%
3 yr--60%--47%
Burke et al., 20061201 yr--37.8%--29.4%
2 yr--48.0%--41.3%
3 yr--54.8%--50.3%
4 yr--60.4%--57.8%
Wogen et al., 20031261 yr50%--63%--
Degli Esposti et al., 2002122,1231 yr30.7%9.4%59.9%33.4%24.6%42.0%
Hasford et al., 20071271 yr28.2%--26.4%--
2 yr18.6%--15.3%--
3 yr14.0%--10.6%--
Patel et al., 20071291 yr48.0%--51.9%--
Lachaine et al., 20081282 yr58.9%--60.9%--
Simons et al., 200813033 mo45%
(95% CI 44 to 46%)
--47%
(95% CI 46 to 48%)
--

From: Results

Cover of Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update
Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update [Internet].
Comparative Effectiveness Reviews, No. 34.
Sanders GD, Coeytaux R, Dolor RJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.